What does Imbria Pharmaceuticals, Inc. do?
Imbria Pharmaceuticals is a clinical stage biotechnology company focused on developing novel therapies for cardiometabolic diseases. The company’s work centers on restoring or improving the cell’s ability to produce energy, an essential function that is compromised in several cardiac disorders.
How much did they raise?
The company closed a $57.5m Series B financing round led by Deep Track Capital, with participation from investors including AN Ventures, Catalio Capital Management, Cytokinetics, RA Capital Management, and SV Health Investors. This infusion of capital supports the progression of its lead product candidate.
What are their plans for the money?
With the new funds, Imbria Pharmaceuticals plans to advance its lead product candidate, ninerafaxstat, into a Phase 2b randomized, double-blind, placebo-controlled clinical trial for non-obstructive hypertrophic cardiomyopathy (nHCM) under the FORTITUDE-HCM study. The trial is expected to start in Q2 2025 with topline data anticipated in late 2026, potentially paving the way for improved treatment options in cardiometabolic care.
What have they achieved so far?
Imbria Pharmaceuticals has made significant strides with its lead product candidate, ninerafaxstat, which has already completed multiple Phase 2 clinical trials in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. Additionally, early trials have demonstrated that the compound is well tolerated, supporting its potential as an innovative treatment option for cardiac disorders.
